Navigation Links
Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
Date:12/13/2011

New Rochelle, NY, December 12, 2011A recent article in the New England Journal of Medicine showed that Factor IX gene therapy in patients with hemophilia B was able to convert severe hemophilia to moderate or even mild disease. In a timely commentary, Thierry VandenDriessche, PhD, Methods Editor for Human Gene Therapy and Human Gene Therapy Methods says that this clinical trial represents an important milestone and "demonstrates unequivocally that gene therapy can result in a sustained therapeutic effect in hemophilia B patients." Read the commentary and listen to the accompanying podcast from Human Gene Therapy. Human Gene Therapy and HGT Methods are peer-reviewed journals published by Mary Ann Liebert, Inc..

The clinical trial reported in NEJM "builds on prior work and on encouraging pre-clinical data in non-human primates," states VandenDriessche and coauthor of the commentary with Marinee Chuah, PhD, Department of Gene Therapy & Regenerative Medicine, Free University of Brussels and the Center for Molecular and Vascular Biology, University of Leuven, Belgium. It demonstrated that injection of an adeno-associated virus (AAV) vector carrying the gene for the clotting factor FIX into patients with severe hemophilia B led to efficient delivery of the gene into liver cells and sufficient production of the FIX protein to transform the disease from severe to a moderate or mild form of hemophilia, although it does not represent a cure. This effect has been stable and has eliminated or substantially reduced the need for the patients to receive standard protein replacement, which is cumbersome and expensive. Substantial improvements in vector technology set the stage for this success; these included a self-complementary genome to increase efficiency pioneered by R. Jude Samulski, PhD, Director, Gene Therapy Center, University of North Carolina at Chapel Hill, and the use of a novel AAV capsid from a natural rhesus monkey isolate called AAV8, which was discovered and developed by James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy and Human Gene Therapy Methods, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Recently published articles in Human Gene Therapy document the development and optimization of the AAV vectors used to deliver the FIX gene in this clinical trial. Two key papers are:

"The successful treatment of patients with hemophilia B with gene therapy is a landmark event representing the culmination of over 20 years of work by many laboratories," says James M. Wilson, MD, PhD. "We are delighted that Human Gene Therapy was a venue for publishing critical aspects of the development of this product."


'/>"/>

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2165
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. BUSM faculty author commentary on the global challenges of emerging viral infections
2. Expert commentary on Earth Days 40th anniversary
3. SectorWatch.biz Issues Commentary for Investors of Homeland Defense Companies FOUR, MAGS, NSSC, PNTR, BCO, and CKP
4. New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy
5. American Migraine Foundation launches new podcast series
6. New American Chemical Society podcast: Tiny sea creature and a new medical adhesive
7. LSUHSC conducts landmark study of mid, long-term health effects of oil exposure
8. Landmark report reveals immense burden of osteoporotic fractures in Europe
9. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
10. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
11. Fruit flies use horizontal landmarks for altitude control, says Caltech research team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Commentary and podcast on landmark gene therapy clinical trial for hemophilia B
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology: